Chinese pharma "soon to be a world force"

1 June 2000

The Chinese pharmaceutical industry will soon become a world force, ifall goes according to the plans set out in the 10th Five-Year Plan (2001-2005), Yu Deming, director of the State Economic and Trade Commission's pharmaceutical department, has said.

Mr Yu, who is responsible for the reform and development of China's pharmaceutical industry, told the fourth Beijing Biotechnological and Pharmaceutical Forum last month that China plans to create 12 large pharmaceutical firms to rival the leading internationals, sharpening the competitive edge of its lumbering drug sector in the worldwide market, notes a report carried on the Asia Pulse news service.

The report quoted Mr Yu as saying that the new firms will have priority for technical renovation and R&D in both the domestic and international markets, and that another key project is the development of biological engineering. The companies' goals will be to become major developers of new technology as well as leading producers of medicines, he said; many of the 6,300 drug firms now operating in China are small and have no qualities to distinguish them from their competitors. Chinese firms must also increase their cooperation with overseas counterparts, he said.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight